Prosecution Insights
Last updated: April 19, 2026

Avidity Biosciences, Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
3
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19376782 COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES WHITEMAN, BRIAN A 1636 Non-Final OA Oct 31, 2025
19267387 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY CHONG, KIMBERLY 1636 Non-Final OA Jul 11, 2025
19097593 ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING LOCKARD, JON MCCLELLAND 1647 Final Rejection Apr 01, 2025
19097573 ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING PUTTLITZ, KARL J 1646 Final Rejection Apr 01, 2025
16649572 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING GIBBS, TERRA C 1635 Final Rejection Mar 20, 2020

Managing Avidity Biosciences, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month